Key result
Aspirin should be widely used in secondary prevention of occlusive vascular events and considered in primary prevention for individuals with a 10-year coronary event risk of ≥10%.
Why the study?
Does aspirin reduce premature deaths and myocardial infarctions in primary and secondary prevention of cardiovascular diseases?
Does aspirin reduce premature deaths and myocardial infarctions in primary and secondary prevention of cardiovascular diseases?
Aspirin should be widely used for secondary prevention of cardiovascular events and considered for primary prevention in high-risk individuals.
Answers are grounded in this paper and cite their sources.
Supports aspirin in secondary and high-risk primary prevention; leaves open updated risk thresholds with contemporary therapies.
The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention. Aspirin should be far more widely used in a wide range of patients who have suffered a prior occlusive vascular event and in all patients suffering acute MI or occlusive stroke. Finally, in primary prevention, aspirin should be considered for individuals whose 10-year risks of a coronary event are > or = 10%, as an adjunct not alternative to the management of other risk factors. The more widespread and appropriate use of aspirin will avoid many premature deaths in secondary prevention and MIs in primary prevention.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2004) conducted a review in Cardiovascular diseases. Aspirin was evaluated. Aspirin should be widely used in secondary prevention of occlusive vascular events and considered in primary prevention for individuals with a 10-year coronary event risk of ≥10%.
Synapse has enriched 10 related papers. Consider them for comparative context: